EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 F

Ensembl ID : ENSFCAG00000003822
Gene Symbol: CACNA1F
5 Cross references
176 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSFCAG00000012339
Gene Symbol: CACNA1G
5 Cross references
198 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSFCAG00000018843
Gene Symbol: CACNA1H
5 Cross references
213 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 I

Ensembl ID : ENSFCAG00000013500
Gene Symbol: CACNA1I
5 Cross references
195 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 S

Ensembl ID : ENSFCAG00000004605
Gene Symbol: CACNA1S
5 Cross references
266 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSFCAG00000012895
Gene Symbol: CNR2
5 Cross references
196 Possible Orthologues:

Carbonic Anhydrase 1

Ensembl ID : ENSFCAG00000022214
Gene Symbol: CA1
5 Cross references
288 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSFCAG00000029058
Gene Symbol: CA12
5 Cross references
215 Possible Orthologues:

Carbonic Anhydrase 14

Ensembl ID : ENSFCAG00000013934
Gene Symbol: CA14
5 Cross references
211 Possible Orthologues:

Carbonic Anhydrase 2

Ensembl ID : ENSFCAG00000005137
Gene Symbol: CA2
5 Cross references
285 Possible Orthologues:

Carbonic Anhydrase 3

Ensembl ID : ENSFCAG00000031511
Gene Symbol: CA3
5 Cross references
310 Possible Orthologues:

Carbonic Anhydrase 4

Ensembl ID : ENSFCAG00000009073
Gene Symbol: CA4
5 Cross references
334 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).